Evidence map›Paper›PMID 41066009›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2025

Acidifying agents impact erlotinib and gefitinib pharmacokinetic parameters and elevate liver enzymes in Wistar rats.

Amsha S Alsegiani, Aliyah Almomen, Maria Arafah, Nourah Z Alzoman, Abdullah K Alshememry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amsha S Alsegiani *Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, 11451, Riyadh, Saudi Arabia.
Aliyah Almomen *Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, 11451, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0002-0181-6330
Maria ArafahDepartment of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Nourah Z AlzomanDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, 11451, Riyadh, Saudi Arabia.
Abdullah K AlshememryDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. aalshememry@ksu.edu.sa.

Funding

King Saud University RSP2024R490
6 · The paper itself

Abstract

Erlotinib (ERL) and Gefitinib (GEF) are weakly basic drugs with pH-dependent solubility profiles mainly dependent on stomach pH. We proposed possible drug and/or food-drug interactions with acidifying agents. Citric acid (CA) and phosphoric acid (PPA) are the most common acidifying agents used in food and medication to treat certain conditions. This study evaluated the impact of concomitant consumption of CA and PA on ERL and GEF pharmacokinetic parameters (PKs). The PKs of ERL and GEF were investigated in rats after four weeks of CA and PPA consumption in low (175 mg/kg) and high (100 mg/kg) doses using UPLC-MS/MS. Data indicated that acidifying agents altered PKs of ERL and GEF dose-dependently. High doses of CA and PPA significantly increased the Cmax of ERL by 103% and 218%, the AUC

Indexed as

Citric acidErlotinibGefitinibPharmacokineticsPhosphoric acidUPLC-MS/MS

Identifiers

PMID41066009
PMCPMC12511468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.